Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277066 | 0.98 | EPHX2 (0.47) | EPHX2APPPTGS1PDE4ALMNA | |
| SCHEMBL4269533 | 0.98 | EPHX2 (0.47) | EPHX2APPPTGS1PDE4ALMNA | |
| SCHEMBL4274897 | 0.98 | EPHX2 (0.47) | EPHX2APPPTGS1PDE4ALMNA | |
| SCHEMBL4268584 | 0.98 | EPHX2 (0.47) | EPHX2APPPTGS1PDE4ALMNA | |
| SCHEMBL14244113 | 0.98 | EPHX2 (0.47) | EPHX2APPPTGS1PDE4ALMNA | |
| SCHEMBL4269751 | 0.98 | EPHX2 (0.47) | EPHX2APPPTGS1PDE4ALMNA | |
| SCHEMBL4275028 | 0.92 | — | — | |
| SCHEMBL1932856 | 0.81 | — | — | |
| SCHEMBL9295184 | 0.81 | EPHX2 (0.50) | EPHX2APPPTGS1PDE4ALMNA | |
| SCHEMBL9295186 | 0.81 | EPHX2 (0.50) | EPHX2APPPTGS1PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094729-A1 | ABETA ANTIBODY PARENTERAL FORMULATION | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008071394-A1 | ABETA ANTIBODY PARENTERAL FORMULATION | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | WO | claimed |
| CN-110869050-B | Bispecific antibody formulations | 豪夫迈·罗氏有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-3071237-B1 | ANTIBODY-DRUG CONJUGATE LYOPHILISED FORMULATION | GENMAB AS (DK) | 2024-06-26 | — | — | EP | disclosed |
| EP-3402465-B1 | FORMULATION FOR ANTIBODY AND DRUG CONJUGATE THEREOF | GENMAB AS (DK) | 2024-03-13 | — | — | EP | disclosed |
| US-20240024312-A1 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-01-25 | — | — | US | disclosed |
| US-20240009151-A1 | FORMULATIONS OF AZOBENZENE PHOTOREACTIVE COMPOUNDS | BAYON THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20240000826-A1 | METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE WITH CYCLODEXTRINS | HERCULES CAPITAL, INC., AS AGENT | 2024-01-04 | — | — | US | disclosed |
| US-20230357451-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230330133-A1 | METHODS FOR THE TREATMENT OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS | HERCULES CAPITAL, INC., AS AGENT | 2023-10-19 | — | — | US | disclosed |
| WO-2001090068-A2 | MANNICH BASE PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE A MODULATORS OF PROTEIN KINASES | SUGEN, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-6184378-B1 | PIGMENTS, LASER DYES AND PRECURSORS FOR PREPARING FLUORESCENT DYES, POLYMERIC COLORANTS, | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-06 | — | — | US | disclosed |
| US-6143905-A | REACTING 1,7-DIBROMOPERYLENE-3,4,9,10-TETRACARBOXYLIC DIANHYDRIDE OR TETRACARBOXYLIC ACID IN PRESENCE OF APROTIC SOLVENT WITH A PRIMARY AMINE TO FORM DIIMIDE, REACTING DIIMIDE WITH AROMATIC ALOCHOL OR THIOL, AND HYDROLYZING | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
| EP-0869959-B1 | 1,7-DISUBSTITUTED PERYLENE-3,4,9,10-TETRACARBOXYLIC ACIDS AND DIANHYDRIDES AND DIIMIDES OF SAID ACIDS | BASF AG (DE) | 2000-05-17 | — | — | EP | disclosed |
| US-6063181-A | 1,7-disubstituted perylene-3,4,9, 10-tetracarboxylic acids, their dianhydrides and diimides of said acids | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | disclosed |
| EP-0873342-A1 | 1,7-DIAROXY- OR 1,7-DIARYLTHIO-SUBSTITUTED PERYLENE-3,4,9,10-TETRACARBOXYLIC ACIDS AND THEIR DIANHYDRIDES AND DIIMIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-28 | — | — | EP | disclosed |
| EP-0869959-A1 | 1,7-DISUBSTITUTED PERYLENE-3,4,9,10-TETRACARBOXYLIC ACIDS AND DIANHYDRIDES AND DIIMIDES OF SAID ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997022607-A1 | 1,7-DIAROXY- OR 1,7-DIARYLTHIO-SUBSTITUTED PERYLENE-3,4,9,10-TETRACARBOXYLIC ACIDS AND THEIR DIANHYDRIDES AND DIIMIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997022608-A1 | 1,7-DISUBSTITUTED PERYLENE-3,4,9,10-TETRACARBOXYLIC ACIDS AND DIANHYDRIDES AND DIIMIDES OF SAID ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024312-A1 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | DPP4, NT5C, DPP7 | EPHX2 3252/4885APP 1647/4885PTGS1 3187/4885 |
| US-20230330133-A1 | METHODS FOR THE TREATMENT OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS | GYS2, CETP, HPSE | EPHX2 694/4885APP 2089/4885PTGS1 2987/4885 |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | AGPS, DDOST, ALG1 | EPHX2 481/4885APP 377/4885PTGS1 4046/4885 |
| US-20240000826-A1 | METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE WITH CYCLODEXTRINS | ADRA1D, PDE6D, PDE4D | EPHX2 1122/4885APP 1010/4885PTGS1 2272/4885 |
| US-20240009151-A1 | FORMULATIONS OF AZOBENZENE PHOTOREACTIVE COMPOUNDS | CRY1, PDE6C, PDE6D | EPHX2 2396/4885APP 954/4885PTGS1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.